Irinotecan Phenobarbital

Kitagawa C, Ando M, Ando Y et al. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase lAl gene and irinotecan toxicity. Pharmacogenet Genomics 2005 15 35 1. 

Ethinyl estradiol, buprenorphine ferulic acid, genistein naltrexone (low), naloxone (low), SN-38 (active metabolite of irinotecan) alizarin, quinalizarin, retigabine Bilirubin, chloropheno- Atazanavir, indinavir, xypropionic acid, chrysin, ketoconazole (AT, = 3 pM) clofibrate, 3-MC, oltipraz, phenylpropionic acid, phenobarbital, clotrimazole, rifampin, and St. John s wort. WY-14643 Response elements for AhR, CAR, GR, PPAR-a, PXR, Nrf2 (antioxidant response element) have been identified... 

IRINOTECAN 1. ANTIBIOTICS-rifampicin 2. ANTICANCER AND IMMUNOMODULATING DRUGS - dexamethasone 3. ANTIDEPRESSANTS -St John s wort 4. ANTI EPILEPTICS -carbamazepine, phenobarbital, phenytoin 1 plasma concentrations of irinotecan and risk of 1 therapeutic efficacy. The effects may last for 3 weeks after discontinuation of CYP-inducer therapy Due to induction of CYP3A4-mediated metabolism of irinotecan Avoid concomitant use when ever possible if not, t dose of irinotecan by 50%... 

---